| Name | Title | Contact Details |
|---|
We are a clinical stage biotech startup, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is the founder of five biotech companies and was previously President of Global R&D and Chief Scientific Officer at Teva. He has directed the development of multiple innovative drug products leading to 35 approvals between 2012-2018.
Secant Pharma is a Feasterville Trevose, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
SSCI is a West Lafayette, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Falks Woodland Pharmacy is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.